Brokerages expect that Quanterix Corp (NASDAQ:QTRX) will report sales of $7.88 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Quanterix’s earnings, with the lowest sales estimate coming in at $7.83 million and the highest estimate coming in at $7.93 million. The company is expected to report its next quarterly earnings results on Tuesday, August 21st.
On average, analysts expect that Quanterix will report full-year sales of $34.25 million for the current fiscal year, with estimates ranging from $34.00 million to $34.45 million. For the next year, analysts anticipate that the company will post sales of $52.28 million per share, with estimates ranging from $50.55 million to $54.09 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Quanterix.
Quanterix (NASDAQ:QTRX) last released its quarterly earnings data on Wednesday, May 9th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.08).
Several equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Quanterix from a “sell” rating to a “hold” rating in a research report on Tuesday, May 22nd. BTIG Research reissued a “buy” rating and issued a $26.00 price objective on shares of Quanterix in a research report on Sunday, May 13th. Finally, ValuEngine raised shares of Quanterix from a “hold” rating to a “buy” rating in a research report on Monday, June 11th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. Quanterix has an average rating of “Buy” and an average target price of $26.50.
Shares of Quanterix traded down $0.86, hitting $14.56, during trading hours on Friday, MarketBeat reports. The company’s stock had a trading volume of 1,308 shares, compared to its average volume of 147,068. Quanterix has a 1-year low of $14.14 and a 1-year high of $24.81. The firm has a market capitalization of $335.33 million and a P/E ratio of -1.80.
In other news, SVP Ernest Orticerio sold 25,000 shares of the stock in a transaction on Tuesday, June 5th. The shares were sold at an average price of $17.15, for a total value of $428,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 31.60% of the stock is owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in the company. Flagship Pioneering Inc. acquired a new stake in Quanterix during the 4th quarter valued at $43,595,000. Millennium Management LLC acquired a new stake in Quanterix during the 4th quarter valued at $11,014,000. Park West Asset Management LLC acquired a new stake in Quanterix during the 4th quarter valued at $4,796,000. Royce & Associates LP acquired a new stake in Quanterix during the 4th quarter valued at $4,382,000. Finally, BlackRock Inc. acquired a new stake in Quanterix during the 1st quarter valued at $3,439,000. 45.71% of the stock is owned by institutional investors.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer.
Get a free copy of the Zacks research report on Quanterix (QTRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.